李冰 副主任医师，副教授
硕士招生类型：学术型；专业型
硕士招生专业：内科学（呼吸内科学）
博士招生类型：学术型；专业型
博士招生专业：内科学（呼吸内科学）
所在院系：附属肺科医院
联系方式：libing044162@163.com；Tel:**
课题组链接：
研究方向
主要任职
科研业绩

呼吸系统感染性疾病与病原微生物特性的研究，非结核分枝杆菌感染的基础和临床研究，呼吸危重症的基础和临床研究Respiratory infectious diseases and pathogenic microorganisms, non-tuberculous mycobacterial infections, respiratory critical disease
上海市医学会感染与化疗专科分会委员会青年委员(Youth Committee of Shanghai Medical Association Infection and Chemotherapy Branch)；
上海市医学会内科专科分会委员会青年委员(Youth Committee of the Shanghai Medical Association Internal Medicine Branch Committee)
致力于非结核分枝杆菌（NTM）肺部感染的研究，尤其以NTM肺病诊疗和NTM耐药机制的研究为特色。主持国家自然科学基金、上海市科委自然基金等课题5项。获得上海市人才发展资金，上海市卫计委“新优青”，上海“医苑新星”优秀青年专科医师，上海“医苑新星”优秀青年医师等人才项目。成果多次发表在Journal of Infectious Disease、Antimicrobial Agents and Chemotherapy、Journal of Clinical Microbiology等微生物感染领域高质量杂志。第一／通讯作者发表SCI论著16篇，JCR I区杂志6篇，单篇最高他引113次。研究成果在ASM、ERS等国际会议交流汇报。第一排名获上海市职工先进操作方法创新奖、上海市卫生计生行业青年五四奖章，上海市医务工会“星光计划”一等奖、上海市医务工会“星光计划”创新之星奖。
Professor Li is dedicated to the research on non-tubercular mycobacterium tuberculosis (NTM) pulmonary infection, especially featuring the diagnosis and treatment of NTM pulmonary disease and the research on NTM drug resistance mechanism. He presided over 5 projects including the National Natural Science Foundation of China and the Natural Science Foundation of Shanghai Municipal Science and Technology Commission. Won the talent development fund of Shanghai, the "New Excellent Youth" of Shanghai Municipal Health and Family Planning Commission, the outstanding young specialist doctors of Shanghai "Medical Garden New Star", the outstanding talented young doctors of Shanghai "Medical Garden New Star". His research results have been published several times in the high-quality journals of microbial infection such as Journal of Infectious Disease、Antimicrobial Agents and Chemotherapy、Journal of Clinical Microbiology. He has published 16 SCI papers, 6 of which are in JCR I journals, and one paper was cited 113 times. He communicated and reported my research results at ASM, ERS and other international conferences, and won the second prize of outstanding young papers at the 2017 national academic conference on infectious diseases and antimicrobial chemotherapy. He won the advanced operating method innovation award of Shanghai workers, the youth May 4th medal of Shanghai health and family planning industry, the first prize of "star light plan" of Shanghai medical workers' union, and the innovation star award of "star light plan" of Shanghai medical workers' union.
代表性论文（第一/通讯作者）：Representative papers (first/correspondent author):
1.Bing Li（第一）, Liyun Xu, Qi Guo, Jianhui Chen, Yanan Zhang, Wenpan Huang, Zhemin Zhang, Lizhong Han, Xiaogang Xu, Haiqing Chu. GenSeizer: A Multiplex PCR-based Targeted Gene Sequencing Platform for Rapid and Accurate Identification of Major Mycobacterium Species. J Clin Microbiol. 2020 Oct;5 accepted. (IF 5.897)；
2.Shaoyan Zhang, Yuzhen Zou, Qi Guo, Jianhui Chen, Liyun Xu, Xiaoyu Wan, Zhemin Zhang, Bing Li（共通讯）, Haiqing Chu. AR-12 Exhibits Direct and Host-targeted Antibacterial Activity toward Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2020, 648(8)（IF 4.904）；
3.Qi Guo, Jianhui Chen, Shaoyan Zhang, Yuzhen Zou, Yongjie Zhang, Dongdong Huang, Zhemin Zhang, Bing Li（共通讯）, Haiqing Chu. Efflux Pumps Contribute to Intrinsic Clarithromycin Resistance in Clinical, Mycobacterium abscessus Isolates, Infect Drug Resist. 2020, 13:447-454. (IF 2.984)；
4.Bing Li（第一）, Qi Guo#, Yanhua Mao#, Yuzhen Zou, Yongjie Zhang, Zhemin Zhang, Haiqing Chu*, Genetic Evolution of Mycobacterium abscessus Conferring Clarithromycin Resistance During Long-term Antibiotic Therapy, Canadian Respiratory Journal,2020, Article ID ** (IF 1.8)；
5.Bing Li（第一）, Meiping Ye, Lan Zhao, Qi Guo, Jianhui Chen, Benyong Xu, Mengling Zhan, Yongjie Zhang, Zhemin Zhang, Haiqing Chu. Glycopeptidolipid Genotype Correlates with the Severity of Mycobacterium abscessus Lung Disease, J Infect Dis. 2020:221 (Suppl 2) ? S257 (IF 5.0)；
6.Chen J, Zhao L, Mao Y, Ye M, Guo Q, Zhang Y, Xu L, Zhang Z, Li B（共通讯）, Chu H. Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease. Front Microbiol. 2019 Aug 23;10:1977. doi: 10.3389/fmicb.2019.01977. eCollection 2019. (IF 4.235)；
7.Mingyan Wu#, Bing Li（共一）, Qi Guoa, Liyun Xu, Yuzhen Zou, Yongjie Zhang, Mengling Zhan, Benyong Xu, Meiping Ye, Fangyou Yu, Zhemin Zhang*, Haiqing Chu*. Detection and Molecular Characterization of Amikacin-resistant Mycobacterium abscessus Isolated from Patients with Pulmonary Disease. Journal of Global Antimicrobial Resistance. 2019 May 20. pii: S2213-7165(19)30126-2. (IF 2.706)；
8.Li B（第一）, Ye M, Guo Q, Zhang Z, Yang S, Ma W, Yu F, Chu H. Determination of MIC Distribution and Mechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00175-18. (IF 4.904)；
9.Li B（第一）, Yang S, Chu H, Zhang Z, Liu W, Luo L, Ma W, Xu X. Relationship between Antibiotic Susceptibility and Genotype in Mycobacterium abscessus Clinical Isolates. Front Microbiol. 2017 Sep 14;8:1739. (IF 4.235)；
10.Liu W, Li B（共一）, Chu H, Zhang Z, Luo L, Ma W, Yang S, Guo Q. Rapid detection of mutations in erm(41) and rrl associated with clarithromycin resistance in Mycobacterium abscessus complex by denaturing gradient gel electrophoresis. J Microbiol Methods. 2017 Dec;143:87-93. (IF 1.707)；
11.Luo L, Liu W, Li B（共一）, Li M, Huang D, Jing L, Chen H, Yang J, Yue J, Wang F, Chu H, Zhang Z. Evaluation of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Mycobacterium abscessus Subspecies According to Whole-Genome Sequencing. J Clin Microbiol. 2016 Dec;54(12):2982-2989. (IF 5.897)；
12.Li B（第一）, Ren S, Li X, Wang Y, Garfield D, Zhou S, Chen X, Su C, Chen M, Kuang P, Gao G, He Y, Fan L, Fei K, Zhou C, Schmit-Bindert G. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer. 2014 Feb;83(2):146-53. (IF 4.702)；
13.Li B（第一）, Ren S, Wang Y, Zhou C, Schmid-Bindert G. Efficacy of third-generation chemotherapeutic agents combined with cisplatin or carboplatin in 3100 Chinese patients with advanced non-small-cell lung cancer. Thorac Cancer. 2013 May;4(2):117-122. (IF 1.1)